Lipocine Inc
LPCN
View Detailed Chart
8.490USD
+0.770+9.97%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
46.02MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+9.97%
5 Days
-5.67%
1 Month
+12.97%
6 Months
+181.13%
Year to Date
+5.73%
1 Year
+124.60%
View Detailed Chart
TradingKey Stock Score of Lipocine Inc
Currency: USD Updated: 2026-02-06Key Insights
Lipocine Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 109 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.88.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lipocine Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lipocine Inc Highlights
StrengthsRisks
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 2139.63% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.20M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -8.35, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.04M shares, increasing 31.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 36.10K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.46.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.875
Target Price
+40.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Lipocine Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lipocine Inc Info
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Ticker SymbolLPCN
CompanyLipocine Inc
CEOPatel (Mahesh V)
Websitehttps://www.lipocine.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68582.600
-1387.530 (-1.98%)
282.580
+22.390 (+8.61%)
2023.420
-28.310 (-1.38%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
